Table a2 Stratified analyses by blinding and intention to treat analysis

From: Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials

Outcome

Trials (patients)

RR* (95% CI)

P- value

P- value for interaction test

Blinding

 Proven or probable IFI

   

0.52

Blinded

4 (2284)

0.62 (0.42, 0.91)

0.01

 

Not blinded

14 (2518)

0.71 (0.52, 0.98)

0.27

 

 Invasive aspergillosis

   

0.60

Blinded

4 (2284)

0.47 (0.23, 0.98)

0.04

 

Not blinded

11 (22196)

0.59 (0.37, 0.95)

0.03

 

 IFI-related mortality

   

0.88

Blinded

3 (1686)

0.68 (0.19, 2.40)

0.54

 

Not blinded

12 (2586)

0.75 (0.49, 1.15)

0.19

 

 IA-related mortality

   

0.60

Blinded

2 (1084)

0.84 (0.15, 4.91)

0.85

 

Not blinded

7 (1530)

0.46 (0.12, 1.77)

0.26

 

 Overall mortality

   

0.23

Blinded

4 (2284)

0.92 (0.76, 1.11)

0.36

 

Not blinded

12 (2586)

1.07 (0.90, 1.28)

0.44

 

ITT analysis

 Proven or probable IFI

   

0.83

ITT

4 (1445)

0.74 (0.46, 1.17)

0.2

 

No ITT

14 (3357)

0.69 (0.44, 1.07)

0.1

 

 Invasive aspergillosis

   

0.55

ITT

5 (1800)

0.47 (0.27, 0.80)

0.006

 

No ITT

10 (2703)

0.58 (0.37, 0.91)

0.02

 

 IFI-related mortality

   

0.60

ITT

5 (1280)

0.60 (0.27, 1.33)

0.21

 

No ITT

10 (2992)

0.77 (0.49, 1.22)

0.27

 

 IA-related mortality

   

NA

ITT

1 (59)

Not estimable

NA

 

No ITT

8 (2555)

0.62 (0.23, 1.71)

0.36

 

 Overall mortality

   

NA

ITT

0 (0)

Not estimable

NA

 

No ITT

16 (4870)

1.00 (0.88, 1.13)

0.96

 
  1. Abbreviations: CI=confidence interval; IA=invasive aspergillosis; IFI=invasive fungal infection; ITT=intention-to-treat; NA=not applicable; RR=relative risk. *RR<1 represents an advantage of mould-active coverage compared with fluconazole using a random-effects model.